We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos and AstraZeneca Enter new Drug Discovery Collaboration
News

Galapagos and AstraZeneca Enter new Drug Discovery Collaboration

Galapagos and AstraZeneca Enter new Drug Discovery Collaboration
News

Galapagos and AstraZeneca Enter new Drug Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos and AstraZeneca Enter new Drug Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that its service division, BioFocus DPI, has entered into new drug discovery collaboration with AstraZeneca. This is the second program between the two companies under an agreement signed in August 2006.

In this new collaboration, BioFocus DPI will perform medicinal chemistry, computational chemistry and supporting biology and ADMET services for an AstraZeneca drug discovery program. Total contract value for Galapagos is €620,000.

"Extending our existing partnership and securing further projects with AstraZeneca is a high priority for us," said Onno van de Stolpe, Chief Executive Officer of Galapagos.

"This latest collaboration demonstrates the positive working relationship and establishes our position as a proven partner specialized in drug discovery services," he added.

"BioFocus DPI's commitment to delivering projects of high quality and on time has been the main driver of AstraZeneca's decision to enter into a new agreement with BioFocus DPI. We have been pleased with the level of progress thus far and expect that BioFocus DPI's expanded ADMET and predictive drug discovery capabilities will be key contributors in advancing this hit-to-lead program," added Dr. Lars-Erik Arvidsson, Vice President R&D Lund, AstraZeneca.

Advertisement